Sales Milestone Payment. The following one-time non-refundable sales milestone payments shall be payable by BMS to BN when [***] set forth below. Milestone Event Milestone Payment [***] first exceed $[***] $ [***] [***] first exceed $[***] $ [***] [***] first exceed $[***] $ [***] [***] first exceed $[***] $ [***] Total $ 495,000,000 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(2), (4), (5) and (6) and 230.406 BMS shall pay to BN the above one-time sales milestone payments within [***] after the end of [***] during which the specified milestone event if first achieved by BMS, its Affiliates or its Sublicensees, but in any event shall not exceed $495 million in the aggregate. For clarity, [***] of a [***] (as determined in the definition of [***]) shall be taken into account for purposes of [***] with respect to the above milestone events and the [***] in [***] below.
Sales Milestone Payment. Within thirty (30) days after the end of the first calendar year in which worldwide Net Sales of the Product (including any Product Line Extensions and including any Incremental Net Sales generated by Acura’s Co-Promotion activities (but excluding Net Sales generated in a country where the Royalty Term has expired or been terminated, after the later of (i) such expiration or termination and (ii) any inventory sell-off by Egalet under Section 14.9)) reach $150 million during such calendar year, Egalet shall make a non-refundable, non-creditable payment to Acura of twelve and one-half million dollars ($12,500,000), in immediately available funds by wire transfer (the “Sales Milestone Payment”), with [*****].
Sales Milestone Payment. X4 shall pay Genzyme the following one-time, non-refundable, non-creditable milestone payments [***] after the first achievement of the corresponding Milestone Event by X4, its Sublicensees and their respective Affiliates: Milestone Event Milestone Payment [***] [***] [***] [***] [***] [***]
Sales Milestone Payment. Kos will pay to Jerini a one-time, non-creditable, non-refundable payment of * * * within * * * following the end of the first calendar year during which aggregate annual Net Sales of the first Licensed Product in the Territory was at least * * * for such year.
Sales Milestone Payment. The sales milestone payments indicated below shall be payable by BMS to Ambrx when the aggregate, combined annual Net Sales in a Calendar Year for a particular Product in the Territory by BMS, its Affiliates and Sublicensees for a given Calendar Year period first reach or exceed the Net Sales threshold amounts set forth below, provided that each of the indicated sales milestone payments will be made in 3 equal annual installments in each Calendar Year after the Net Sales threshold amount triggering the milestone payment is first reached or exceeded, but only in those Calendar Years where such Net Sales threshold amount continues to be met or exceeded.
Sales Milestone Payment. The sales milestone payments indicated below shall be payable by BMS to Ambrx when the aggregate, combined annual Net Sales in a Calendar Year for a particular Product in the Territory by BMS, its Affiliates and Sublicensees for a given Calendar Year period first reach or exceed the Net Sales threshold amounts set forth below, provided that each of the indicated sales milestone payments will be made in 3 equal annual installments in each Calendar Year after the Net Sales threshold amount triggering the milestone payment is first reached or exceeded, but only in those Calendar Years where such Net Sales threshold amount continues to be met or exceeded. Milestone Event Milestone Payment Aggregate annual Net Sales of Product in Territory first reach [***] [***] Aggregate annual Net Sales of Product in Territory first reach [***] [***] The above milestone payment amounts are noncreditable and nonrefundable, and payable only once, such that the maximum amount payable under this Section 8.3 is one hundred fifty million Dollars ($150 million). The payments payable by BMS to Ambrx under this Section 8.3 shall be paid within sixty (60) days following the end of the applicable Calendar Year.
Sales Milestone Payment. Subject to the Contingent Payment Termination Date and the set-off rights of Buyer pursuant to Section 2.7(h) and Article 9 hereof, Buyer shall make a one-xxxx Xxxxxx Contingent Payment (the “Sales Milestone Payment”) equal to the Sales Milestone Payment Amount following achievement of the Sales Milestone.
Sales Milestone Payment. In addition to the payments referenced in Sections 4.1 through 4.4 above, Novartis shall pay XOMA the following sales milestone payments following the first respective Calendar Quarter in which the total Net Sales of all Products in the Territory first reach or exceed the thresholds specified in the table below for the Calendar Year in which such Calendar Quarter occurs. Following XOMA’s receipt of a Sales & Royalty Report for a Calendar Quarter of a Calendar Year, if a sales milestone payment has been achieved, [*] Novartis shall pay XOMA the associated milestone payment within [*]. In the interest of clarity, (a) XOMA may earn more than one payment pursuant to this Section 4.5. in a given year (e.g., if total Net Sales of all Products in the Territory are US$[*] in a Calendar Year, and no previous sales milestone had been achieved under this Section 4.5, then all four (4) sales milestones would be achieved, and all four (4) associated milestone payments would be earned, in such Calendar Year), and (b) the aggregate of all payments made pursuant to this Section 4.5 shall not exceed US$[*]. Sales milestone Associated milestone payment Annual Net Sales first reach US$[*] US$[*] Annual Net Sales first reach US$[*] US$[*] Annual Net Sales first reach US$[*] US$[*] Annual Net Sales first reach US$[*] US$[*] [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Sales Milestone Payment. In addition to the payments referenced in Sections 4.1 through 4.4 above, Novartis shall pay XOMA the following one-time sales milestone payments following the first respective Calendar Quarter in which the total Net Sales of all Products in the Territory first reach or exceed the thresholds specified in the table below for the Calendar Year in which such Calendar Quarter occurs. Following XOMA’s receipt of a Sales & Royalty Report for a Calendar Quarter of a Calendar Year, if a sales milestone payment has been achieved, [*] Novartis shall pay XOMA the associated milestone payment within [*]. In the interest of clarity, (a) [*], and no previous sales milestone had been achieved under this Section 4.5, then [*], and all [*] (b) each [*] and (c) [*] Sales Milestone Associated Milestone Payment Annual Net Sales first reach US$[*] US$[*] Annual Net Sales first reach US$[*] US$[*] Annual Net Sales first reach US$[*] US$[*] Annual Net Sales first reach US$[*] US$[*]
Sales Milestone Payment. For each * Licensed Product with respect to which *, Pfizer will make * to Celldex of * in the event * of such * Licensed Product *. For the avoidance of doubt, *.
